Castuner

CME/CE

ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

Site du podcast

Écouter dans votre application

Épisodes

420 épisodes

  1. Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs 5:30
  2. Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex 8:45
  3. Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load 8:45
  4. The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion 5:45
  5. Potassium Binders to Optimize GDMT Therapy in HFrEF 6:45
  6. CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia 9:00
  7. From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection 5:15
  8. The Binder Selection Playbook: Matching the Right Strategy to the Right Patient 17:15
  9. Optimizing The Management of Patients With Heart Failure With the 6-Minute Walk Test 9:30
  10. Recurrence as the Rule: BD Symptoms Persist and Cycle 5:15
  11. Navigating the Limitations of Current BD Therapies 6:00
  12. Modulating the Bipolar Circuit: Striatal Dopamine and the Muscarinic Opportunity 5:00
  13. The Next Frontier: Addressing Persistent Cognitive Impairment in Bipolar Disorder 6:00
  14. Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum 6:30
  15. The Hidden Danger of IgAN: Pathogenesis and Unmet Needs 6:00
  16. Unmasking IgAN: Achieving Earlier Diagnosis 6:45
  17. Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal 6:30
  18. Navigating KDIGO Guidance in IgAN 4:15
  19. Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN 4:30
  20. Translating Evidence into IgAN Care 8:45
  21. The Evolving Role of Biomarkers in IgAN 4:45
  22. The Future of IgAN Care 5:30
  23. Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders 5:15
  24. Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression 6:00
  25. The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape 7:30
  26. Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens 3:45
  27. Oral GLP-1 RA Therapy in Type 2 Diabetes and High Cardiovascular Risk 33:15
  28. Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy 9:00
  29. A New Lens on DKA: Leveraging the Latest Tech for Improved Patient Outcomes 16:45
  30. Patient Portal: Leveraging Technology to Improve Safety with Clinical Decision-Making for People with Diabetes 15:00
  31. CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs 36:45
  32. Treating Outside the Box: New Pathways to Retinal Vascular Stability 44:00
  33. Addressing the Burden of PH-ILD: Early Recognition, Evidence-Based Management, and Care Coordination 47:15
  34. Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion 16:00
  35. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma 5:30
  36. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients 9:15
  37. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma 5:15
  38. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients 9:45
  39. Hypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis 45:00
  40. Mineralocorticoid Receptor Antagonists in Heart Failure: The Evolving Treatment Landscape 55:00
  41. Overcoming Challenges in Transthyretin Cardiac Amyloidosis 58:45
  42. Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care 7:30
  43. CKD-aP Uncovered Prevalence & Pathophysiology 5:15
  44. When Itching Hurts: Quality of Life Disruption in CKD-aP 5:30
  45. Gabapentinoids: Safety Considerations and Downstream Outcomes 4:15
  46. From Scratch to Strategy: Talking About CKD-aP in Clinical Practice 5:00
  47. Spotlight on Assessment: Tools That Capture CKD-aP 7:30
  48. Reading Between the Lines: What PROMs Reveal About Itch 3:45
  49. What You Don’t See: A Patient’s View of Living with CKD-aP 6:00
  50. Winning the CKD-aP Battle: A United Physician-Nurse Front 5:00